Loading...
•
Jun 30, 2025
Cellebrite Q2 2025 Earnings Report
Cellebrite reported strong revenue and profitability in Q2 2025 with significant year-over-year growth across key metrics.
Key Takeaways
Cellebrite delivered an 18% increase in revenue and a 29% improvement in adjusted EBITDA in Q2 2025. The company posted $19.5 million in net income and free cash flow more than doubled year-over-year.
Revenue reached $113.3 million, growing 18% YoY
Annual recurring revenue climbed 21% to $418.9 million
Adjusted EBITDA margin rose to 24.6% with $27.9 million in adjusted EBITDA
Free cash flow jumped 133% YoY to $29.0 million
Revenue by Segment
Forward Guidance
Cellebrite expects solid growth to continue into Q3 and FY2025, but with slight moderation due to timing of federal contracts.
Positive Outlook
- Q3 revenue expected between $121M–$126M
- FY25 revenue guided to $465M–$475M
- ARR forecasted to reach $460M–$475M for FY25
- Adjusted EBITDA expected to grow to $118M–$123M in FY25
- Strong FCF margin to support strategic initiatives
Challenges Ahead
- Guidance reflects modest adjustments due to timing of federal spending
- Acquisition of Corellium not yet included in forward guidance
- Continued need for FedRAMP authorization limits short-term upside
- R&D and G&A expenses increased YoY
- Dependency on regulatory approval to close strategic deals
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...